RESUMO

Melanoma is the deadliest cutaneous malignancy and its incidence continues to grow. Until 2011, the treatment options for metastatic melanoma were scarce and without any overall survival benefit. The emergence of new targeted therapies for BRAF mutant melanoma (vemurafenib) and immunotherapy (ipilimumab) has changed the standard of care for this disease. The objective of the present review is to summarise the biological background of the new therapeutic approaches in melanoma, focusing on apoptosis resistance, immune modulation and angiogenesis, and the direct translation into clinical practice.

Assuntos

Antineoplásicos/uso terapêutico , Imunoterapia/métodos , Melanoma/terapia , Neoplasias Cutâneas/terapia , Inibidores da Angiogênese/uso terapêutico , Apoptose , Biomarcadores Tumorais/metabolismo , Humanos , Melanoma/imunologia , Melanoma/metabolismo , Proteínas Proto-Oncogênicas B-raf/genética , Neoplasias Cutâneas/imunologia , Neoplasias Cutâneas/metabolismo